I
Isomorphic Labs
Biotech & Life Sciences · London, United Kingdom · Founded 2021
An artificial intelligence company to discover new drugs MoreLess
Isomorphic Labs, founded in 2021, is an AI-driven company dedicated to revolutionizing drug discovery and development. By leveraging the groundbreaking advancements from Google DeepMind, such as AlphaFold, Isomorphic Labs aims to apply machine learning and computational methods to tackle complex biological challenges. The company operates at the intersection of AI, biotechnology, and medicine, focusing on developing predictive and generative models to enhance the efficiency and effectiveness of drug design and medical research.
Supported by the robust infrastructure of Alphabet Inc., Isomorphic Labs combines the agility of a startup with substantial resources and expertise. The leadership team, including notable figures like Sir Demis Hassabis and Colin Murdoch, drives the company's mission to transform how medicine is discovered and delivered. Their approach integrates deep learning, reinforcement learning, and other advanced AI techniques to innovate within the life sciences, aiming to bring better therapeutic solutions to market more swiftly and accurately.
News
Google DeepMind resets leadership: Hassabis becomes chair, Kavukcuoglu takes operational lead
Aug 13, 2026
News
Demis Hassabis: A Framework for Frontier AI and the Dawning of a New Age
Jul 14, 2026
News
Isomorphic Labs in talks to raise over $2B for AI drug discovery
May 9, 2026
Market map
Computational Biology & Chemistry startups in Europe
Market map
UK Techbio landscape
Market map
Deep Tech flywheel in Europe
Company overview
Isomorphic Labs company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 408
- Open positions
- 17
- Dealroom signal
- 96.8
Valuation & funding
Isomorphic Labs funding history
Real financing events remain useful in the public preview; precision and the complete record are the upgrade.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B | May 2026 | $2.1B | $8.4B | GV · MGX · CapitalG · Alphabet | Google | ↗ |
| LATE VC | Mar 2025 | $600M | $2.4B | GV · Thrive Capital | ↗ |
| CORPORATE SPINOUT | Nov 2021 | $0 | $0 | Google DeepMind | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
How Isomorphic Labs is moving
Follow workforce and web momentum over time, compare each signal with similar companies, and spot changes before they show up in a financing event.
Comparisons
Isomorphic Labs compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Isomorphic Labs's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Isomorphic Labs has talent and traffic
team presence
In the news
Latest news about Isomorphic Labs
Recent press, funding announcements, and product moves mentioning Isomorphic Labs — open to read from the original sources.
Market sentiment
What the market is saying about Isomorphic Labs
An AI-synthesized read of the highest-engagement posts about Isomorphic Labs on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Isomorphic Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.